Business & Regulation

MSD describes drug price negotiation program as “sham” and “tantamount to extortion”

Misbranded drugs, unapproved drugs, and companies who don’t know that ophthalmic drugs should be manufactured in a sterile environment…

Amgen’s planned acquisition of Horizon Therapeutics has hit a bump in the road.

There are many players in pharmaceutical pricing, from drug manufacturers to PBMs and pharmacies. Who should take the lead?

Hall Gregg, Chief Portfolio Officer at the Pistoia Alliance, discusses the transformative power of collaboration, innovation, and diversification

What can science learn from patients, and how can patients benefit from being in control of their own health?

Patient-centricity needs to be more than a buzzword. Here’s how Boehringer Ingelheim is weaving it into its culture.

The wait is over. Our annual celebration of the pharma industry’s most influential individuals has returned!

Do investors scrutinize pharma CEOs more closely when they are women?

In Britain and around the world, the investment ecosystem dominated by males needs an urgent shake up.